Vanda Pharmaceuticals logo

Vanda Pharmaceuticals Share Price (NASDAQ: VNDA)

$4.74

0.04

(0.85%)

Last updated on

Check the interactive Vanda Pharmaceuticals Stock chart to analyse performance

Vanda Pharmaceuticals stock performance

as on August 30, 2025 at 1:29 am IST

  • Today's Low:$4.63
    Today's High:$4.74

    Day's Volatility :2.32%

  • 52 Weeks Low:$3.81
    52 Weeks High:$5.55

    52 Weeks Volatility :31.3%

Vanda Pharmaceuticals Stock Returns

PeriodVanda Pharmaceuticals Inc.Sector (Health Care)Index (Russel 2000)
3 Months
10.12%
3.6%
0.0%
6 Months
0.32%
-7.7%
0.0%
1 Year
-6.79%
-12.6%
0.0%
3 Years
-56.2%
9.5%
-4.7%

Vanda Pharmaceuticals Inc. Key Stats

Check Vanda Pharmaceuticals key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$4.7
Open
$4.68
Today's High
$4.74
Today's Low
$4.63
Market Capitalization
$277.7M
Today's Volume
$278.0K
52 Week High
$5.545
52 Week Low
$3.8092
Revenue TTM
$203.5M
EBITDA
$-92.9M
Earnings Per Share (EPS)
$-1.14
Profit Margin
-32.9%
Quarterly Earnings Growth YOY
-0.96%
Return On Equity TTM
-13.01%

Stock Returns calculator for Vanda Pharmaceuticals Stock including INR - Dollar returns

The Vanda Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Vanda Pharmaceuticals investment value today

Current value as on today

₹98,591

Returns

₹1,409

(-1.41%)

Returns from Vanda Pharmaceuticals Stock

₹6,693 (-6.69%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Vanda Pharmaceuticals Stock

-5%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Vanda Pharmaceuticals Stock from India on INDmoney has decreased by -5% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Vanda Pharmaceuticals Inc.

  • Name

    Holdings %

  • BlackRock Inc

    15.45%

  • Vanguard Group Inc

    6.05%

  • Renaissance Technologies Corp

    6.04%

  • Dimensional Fund Advisors, Inc.

    4.38%

  • TANG CAPITAL MANAGEMENT LLC

    3.98%

  • Millennium Management LLC

    3.62%

Analyst Recommendation on Vanda Pharmaceuticals Stock

Rating
Trend

Buy

    85%Buy

    14%Hold

    0%Sell

Based on 7 Wall street analysts offering stock ratings for Vanda Pharmaceuticals(by analysts ranked 0 to 5 stars)

Vanda Pharmaceuticals Share Price Target

What analysts predicted

Upside of 167.23%

Target:

$12.67

Current:

$4.74

Vanda Pharmaceuticals share price target is $12.67, a slight Upside of 167.23% compared to current price of $4.74 as per analysts' prediction.

Vanda Pharmaceuticals Stock Insights

  • Price Movement

    In the last 3 years, VNDA stock has moved down by -56.7%
  • Increasing Revenue

    Revenue is up for the last 2 quarters, 50.04M → 52.59M (in $), with an average increase of 4.9% per quarter
  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -29.49M → -27.20M (in $), with an average increase of 8.4% per quarter
  • VNDA vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.9% return, outperforming this stock by 80.4%
  • VNDA vs ALNY (3 yr)

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 112.6% return, outperforming this stock by 169.3%
  • Price to Sales

    ForVNDA every $1 of sales, investors are willing to pay $1.4, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.5 for every $1 of sales.

Vanda Pharmaceuticals Inc. Financials

Revenue
Profit
Cash Flow
Annually
Quarterly
FY19
FY20
FY21
FY22
FY23
FY24
FY24Y/Y Change
Revenue
$198.8M
↑ 3.18%
Net Income
$-18.9M
↓ 853.29%
Net Profit Margin
-9.51%
↓ 10.81%

Vanda Pharmaceuticals Technicals Summary

Sell

Neutral

Buy

Vanda Pharmaceuticals is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Vanda Pharmaceuticals Inc. Vs Peers

Returns
Ratio's
Overview
Company Name1 Month6 Month1 Year3 Years5 Years
Vanda Pharmaceuticals Inc. logo
11.15%
0.32%
-6.79%
-56.2%
-52.79%
Regeneron Pharmaceuticals, Inc. logo
6.48%
-15.2%
-50.31%
-3.3%
-2.01%
Beone Medicines Ltd logo
1.77%
24.81%
62.78%
79.11%
29.69%
Vertex Pharmaceuticals Incorporated logo
-14.45%
-19.13%
-17.84%
34.68%
41.87%
Alnylam Pharmaceuticals, Inc. logo
13.79%
83.28%
75.87%
111.28%
242.25%

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Ponvory for the treatment of psoriasis and ulcerative colitis. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) a LAI formulation to treat schizophrenia; Bysanti for the acute treatment of bipolar I disorder, schizophrenia, and major depressive disorder; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, and atopic dermatitis. The company's pipeline products also include Imsidolimab, an IL-36R antagonist, for the treatment of generalized pustular psoriasis; VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; VPO-227 for the treatment of secretory diarrhea disorders comprising cholera; Antisense oligonucleotide molecules, including VCA-894A for the treatment of Charcot-Marie-Tooth Disease and Type 2S (CMT2S); and VGT-1849A for the treatment of polycythemia vera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Organization
Vanda Pharmaceuticals
Employees
368
CEO
Dr. Mihael H. Polymeropoulos M.D.
Industry
Health Technology

Key Management of Vanda Pharmaceuticals Inc.

NameTitle
Dr. Mihael H. Polymeropoulos M.D.
Founder, President, CEO & Chairman of The Board
Mr. Kevin Patrick Moran
Senior VP, CFO & Treasurer
Mr. Timothy Williams J.D.
Senior VP, General Counsel & Secretary
Mr. Joakim Wijkstrom
Senior VP & Chief Marketing Officer
Mr. Gunther Birznieks
Senior Vice President of Business Development
Mr. Scott L. Howell
Chief People Officer

Important FAQs about investing in VNDA Stock from India :

What is Vanda Pharmaceuticals share price today?

Vanda Pharmaceuticals share price today is $4.74 as on at the close of the market. Vanda Pharmaceuticals share today touched a day high of $4.74 and a low of $4.63.

What is the 52 week high and 52 week low for Vanda Pharmaceuticals share?

Vanda Pharmaceuticals share touched a 52 week high of $5.55 and a 52 week low of $3.81. Vanda Pharmaceuticals stock price today i.e. is closed at $4.74, lower by 14.52% versus the 52 week high.

How to invest in Vanda Pharmaceuticals Stock (VNDA) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Vanda Pharmaceuticals on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Vanda Pharmaceuticals Shares that will get you 0.3165 shares as per Vanda Pharmaceuticals share price of $4.74 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Vanda Pharmaceuticals Stock (VNDA) from India?

Indian investors can start investing in Vanda Pharmaceuticals (VNDA) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Vanda Pharmaceuticals stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Vanda Pharmaceuticals share’s latest price of $4.74 as on August 30, 2025 at 1:29 am IST, you will get 2.1097 shares of Vanda Pharmaceuticals. Learn more about fractional shares .

What are the returns that Vanda Pharmaceuticals has given to Indian investors in the last 5 years?

Vanda Pharmaceuticals stock has given -52.79% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?